Tscan Therapeutics opened lower at $0.18, compared with its previous close of $0.19. In the last trading session, the stock traded between $0.16 and $0.18. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Tscan Therapeutics is now worth
$ 1.89
Resulting in a loss of
$ 98.11 (98.11%)
Invest with $1
Note: Past profits do not guarantee future returns.
TScan Therapeutics reported Q3 EPS of $(0.25), missing the $(0.19) estimate by 31.58%. Quarterly revenue of $586K beat the $459K consensus estimate by 27.67%. Revenue declined 76.66% YoY from $2.511 million in the same period last year. Loss per share improved from $(0.28) YoY but remained above analyst expectations.
Today
3Sep
Wedbush downgrades TScan Therapeutics to Neutral, cuts PT to $1
Wedbush downgrades TScan Therapeutics (NASDAQ: TCRX) from Outperform to Neutral. Price target lowered from $5 to $1 by analyst David Nierengarten. The $4 reduction in target price signals a sharp revision in valuation expectations.
2mo ago
2Sep
TScan Therapeutics cuts 75% of staff, pauses Phase 3 trial
TScan Therapeutics cuts workforce by approximately 75% to fund pipeline priorities. Enrollment paused in Phase 3 ALLOHA-2 trial due to funding constraints. Focus shifts to in vivo solid tumor therapies targeting PRAME and MAGE-A4. Shares fell 36.95% to $0.42 following the announcement.
Amgen terminates its 2023 collaboration with TScan Therapeutics effective November 10, 2026. The deal, which focused on Crohn’s disease targets, included a $30 million upfront payment to TScan and over $500 million in potential milestones. No termination fees are due.
2mo ago
12Aug
TScan Therapeutics Q2 Results: Sales Fall 66% YoY, EPS Misses
TScan Therapeutics missed Q2 estimates with EPS of $(0.23) vs $(0.21) expected. Sales fell 65.83% YoY to $1.051M, missing the $1.667M forecast. The EPS miss was narrower than the revenue miss, suggesting cost discipline amidst top-line weakness.
3mo ago
24Jun
TScan Therapeutics to join H.C. Wainwright conference
TScan Therapeutics, Inc. will participate in a fireside chat at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026. The webcast will be available on the company's website, with an archived replay accessible for 90 days.
